Clinical Trial Update: Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and feasibility of combining 5-ALA with CV01 ultrasound delivery for recurrent high-grade glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• 5-ALA (5-aminolevulinic acid) (5-aminolevulinic acid)

Snippet

Sponsor: Alpheus Medical, Inc. | Conditions: High Grade Glioma | Phase 1 | Status: COMPLETED